NCT02207309 2024-08-09
Pazopanib Maintenance Phase II
Ludwig-Maximilians - University of Munich
Phase 2 Terminated
Clinical Trials
31 trialsNCT01407562 2022-09-28
Study of Pazopanib, Paclitaxel, and Carboplatin in Patients With Advanced Solid Tumors
Rutgers, The State University of New Jersey
Phase 1 Terminated
NCT03334409 2022-03-31
Pazopanib Hydrochloride With or Without Ascorbic Acid in Treating Patients With Kidney Cancer That Is Metastatic or Cannot Be Removed by Surgery
Academic and Community Cancer Research United
Phase 2 Terminated
NCT02212015 2022-03-22
EVA
Heidelberg University
Phase 2 Terminated
NCT01035658 2021-10-28
Pazopanib/Doxil in Adv Relapsed Plat Sensitive or Resistant Ovarian, Fallopian or Primary Peritoneal Adenocarcinoma
SCRI Development Innovations, LLC
Phase 1/2 Terminated
NCT01548144 2021-09-13
Pazopanib or Pemetrexed and Crizotinib in Advanced Cancer
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT02959554 2021-09-08
NIVOSWITCH
AIO-Studien-gGmbH
Phase 2 Terminated
NCT02055690 2021-05-17
PAZOFOS
The Christie NHS Foundation Trust
Phase 1/2 Terminated
NCT01543802 2021-01-26
NOPASS
Heidelberg University
Phase 2 Terminated
NCT02193152 2020-07-14
Pazopanib in Molecularly Selected Patients With Advanced NSCLC
Washington University School of Medicine
Phase 2 Terminated
NCT01392352 2020-02-13
HYPAZ
Cambridge University Hospitals NHS Foundation Trust
Phase 2 Terminated
NCT02795819 2019-10-24
Study of the Pan-DAC Inhibitor AR-42 and Pazopanib in Advanced Sarcoma and Kidney Cancer
Virginia Commonwealth University
Phase 1 Terminated
NCT02575066 2019-06-27
PASART-2
The Netherlands Cancer Institute
Phase 2 Terminated
NCT01855724 2018-11-07
Clinical Trial to Investigate the Efficacy of Treatment With Gemcitabine/Pazopanib in Patients With Biliary Tree Cancer
Hellenic Cooperative Oncology Group
Phase 2 Terminated
NCT02560012 2018-10-12
Personalized Targeted Inhibitors Treatment in Renal Cell Cancer
The University of Texas Health Science Center, Houston
Phase 2 Terminated
NCT01642017 2018-08-06
VOTRAGE
Institut Claudius Regaud
Phase 1 Terminated
NCT01394211 2018-07-26
Neo-adjuvant Therapy With Anastrozole Plus Pazopanib in Stage II and III ER+ Breast Cancer
University of Arizona
Phase 2 Terminated
NCT01418001 2018-01-11
Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS)
Memorial Sloan Kettering Cancer Center
Phase 1/2 Terminated
NCT01012362 2017-12-28
Study of Pazopanib and Ixabepilone in Patients With Solid Tumors
Masonic Cancer Center, University of Minnesota
Phase 1 Terminated
NCT02113826 2017-11-06
Pazopanib for Metastatic Alveolar Soft Part Sarcoma
Seoul National University Hospital
Phase 2 Terminated
NCT01622660 2017-08-22
Gemcitabine and Pazopanib in Chemotherapy Naïve Patients With Advanced/Metastatic Urothelial Carcinoma Ineligible for Cisplatin-based Chemotherapy
Memorial Sloan Kettering Cancer Center
Phase 2 Terminated
NCT02089802 2017-08-18
OPERA
Interessenverband zur Qualitätssicherung der Arbeit niedergelassener Uro-Onkologen in Deutschland e.
Phase 2 Terminated
NCT01599832 2017-06-08
Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Measuring Effects of Pazopanib Hydrochloride in Patients With Metastatic Kidney Cancer
University of Chicago
Phase NA Terminated
NCT01391611 2017-04-07
Pazopanib in Imatinib Refractory or Intolerant Gastrointestinal Stromal Tumors (GIST)
Stanford University
Phase 2 Terminated
NCT01059656 2016-07-01
DFSP-PAZO
Assistance Publique - Hôpitaux de Paris
Phase 2 Terminated
NCT01716546 2015-10-08
Trial of Panitumumab Cisplatin, Fluourouracil and Docetaxel in Locally Advanced or Metastatic Gastric Cancer
Hellenic Oncology Research Group
Phase 1/2 Terminated
NCT01542047 2015-06-18
A Combination of Pazopanib and Carboplatin in Advanced Solid Malignancies
New Mexico Cancer Research Alliance
Phase 1 Terminated
NCT01080248 2015-06-09
Gemcitabine and Pazopanib in Metastatic Pancreatic Cancer
Washington University School of Medicine
Phase 2 Terminated
NCT01049776 2014-09-19
GW786034 in Patients With Non Small Cell Lung Cancer 3rd Line
Illinois CancerCare, P.C.
Phase 2 Terminated
NCT00945477 2013-11-18
Pazopanib as Second Line Therapy in Patients With Metastatic Prostate Cancer Refractory to Total Androgen Blockade
Illinois CancerCare, P.C.
Phase 2 Terminated
NCT01060514 2013-10-30
Pazopanib + Vinorelbine in Non Small Cell Lung Cancer (NSCLC) and Breast Cancer
Northwestern University
Phase 1 Terminated